On March 11, 2022 the International Rett Syndrome Foundation and the Rett Syndrome Research Trust hosted an Externally-Led Patient-Focused Drug Development meeting to provide an opportunity for the Food and Drug Administration (FDA), biopharmaceutical companies and other key stakeholders to hear directly from families about the symptoms that matter most to them, the impact the disease has on our children’s daily lives, our experiences with currently available treatments and our hopes for the future.

This webinar served to prepare the community in advance of the March 11 meeting with the FDA.